Citizens JMP raised the firm’s price target on HealthEquity (HQY) to $122 from $117 and keeps an Outperform rating on the shares. HealthEquity appears well-positioned to benefit from HSA market expansion, accretion from a favorable member rate mix, and HSA repricing, while continued investment in its technologies and platform is also expected to strengthen the company’s competitive advantage, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity Inc. Reports Strong Q3 Financial Performance
- HealthEquity raises FY26 EPS view to $3.87-$3.95 from $3.74-$3.91
- HealthEquity reports Q3 EPS $1.01, consensus 91c
- Healthequity Inc (HQY) Q3 Earnings Cheat Sheet
- Healthequity’s Growth Potential: Buy Rating Backed by Market Expansion Opportunities and Strategic Positioning